FDA Grants Astellas Fast Track Designation for Peanut Allergy Vaccine

Tokyo-based Astellas has received an FDA Fast Track designation for ASP0892, to reduce or eliminate sensitivity to the three major peanut allergens.

ASP0892 is a part of a new DNA vaccine program designed to stimulate an immune response against a particular protein. The company has launched a Phase I clinical trial to evaluate the safety, tolerability and immune response of ASP0892 in adults allergic to peanuts.

In October 2015, Astellas and Immunomic Therapeutics entered into an agreement to co-develop products for the treatment or prevention of any and all human allergic diseases.